Overview

TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
0
Participant gender:
All
Summary
In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: - To confirm the superiority of TRK-100STP over placebo - To determine the recommended therapeutic dose in the 2 doses of TRK-100STP - To assess the safety of TRK-100STP
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Toray Industries, Inc
Collaborator:
Astellas Pharma Inc
Treatments:
Beraprost
Epoprostenol
Criteria
Inclusion Criteria:

- The CRF patient with primary glomerular disease or nephrosclerosis as the primary
disease

- The patient with progressive CRF

Exclusion Criteria:

- The patient with secondary glomerular disease

- The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty
kidney, polycystic kidney disease, or nephroureterolithiasis